< Back to all news
December 2, 2020

Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome

R. Das, K. McGrath, N. Seiser, K. Smith, S. Uttam, R. E. Brand, K. E. Fasanella, A. Khalid, J. S. Chennat, S. Sarkaria, H. Singh, A. Slivka, H. J. Zeh, A. H. Zureikat, M. E. Hogg, K. K. Lee, A. Paniccia, M. C. Ongchin, J. F. Pingpank, B. A. Boone, A. K. Dasyam, N. Bahary, V. C. Gorantla, J. C. Rhee, R. Thomas, S. Ellsworth, M. S. Landau, N. Paul Ohori, P. Henn, S. Shyu, B. K. Theisen, A. D. Singhi

Clin. Gastroenterol. Hepatol., Dec 02, 2020.

Drs. Das and Singhi led this study on the the role of tumor size difference between preoperative endoscopic ultrasound imaging and postoperative pathology in neoadjuvant-treated pancreatic ductal adenocarcinoma patients as a potential prognostic indicator in subsequent chemotherapeutic management.